Prolepsia forecastYes / no
On 31 December 2027, will Novo Nordisk offer any dose of Wegovy (pill or injection) to US self-paying patients for US$99 a month or less?
As of 17 November 2026, Prolepsia puts the chance of yes at 89%.
89%chance of yes
How Prolepsia reasons
The report Prolepsia wrote with this forecast.
How forecasts are made · Track record
TL;DR
Probability of Yes: 89.3%. Probability of No: 10.7%. The forecast mainly rests on NovoCare keeping its existing $0 first-month Wegovy offer for eligible patients with MASH redeemable on December 31, 2027, not on a nationwide price cut.
Key evidence
NovoCare’s public terms offer eligible adults who are new to Wegovy and have an on-label diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) one full 28-day supply of the 0.25 mg injection at no charge. Uninsured patients can qualify, no third party can be billed for the free fill, and no paid refill is required. The published materials disclose no mandatory delivery or handling fee. This is a prescription fill for a publicly defined group, not a sample. The question expressly allows introductory offers and does not require a positive payment.
The August 2025 enrollment form and terms available in November 2026 describe the same benefit. The program has no published end date. A Novo rare-bleeding-disorder trial program also shows that manufacturer trial offers can persist for years, though one example in a different market does not establish a renewal rate.
The November 2026 price guide puts the cheapest ordinary self-pay fill at $149 for 30 starter tablets. A new offer would need to take at least $50 off that price before any required fees. A targeted starter promotion is a more plausible fallback than a permanent national cut.
Uncertainties
Novo can amend or withdraw the MASH offer, and there is no public commitment to keep it open through December 2027. A webpage alone would not establish that eligible patients could still redeem the offer that day. There is also a narrow interpretation risk that a free fill is treated differently from a self-pay purchase, though the rules focus on whether the patient can obtain a full month without insurance or government assistance. The clearest resolution evidence will be dated program terms and active enrollment or redemption instructions.
Read the full report
TL;DR
Probability of Yes: 89.3%. Probability of No: 10.7%. For December 31, 2027, the decisive offer to track is NovoCare’s $0 MASH starter fill, not the national Wegovy cash price.
Context
The question is about the amount a US patient pays for a full month of FDA-approved Wegovy without insurance reimbursement or government assistance. One authorized offer for a meaningful, publicly defined group is enough. A first fill counts, but it must be open for enrollment or redemption on December 31, 2027, Eastern Time, and any required fees must fit under the $99 cap.
As of November 17, 2026, the NovoCare price guide lists the cheapest ordinary fill at $149 for 30 tablets of the 1.5 mg starter pill. Standard injections cost $349 for 28 days, selected introductory injections cost $199, and Wegovy HD costs $399. A separate offer for patients with a liver disease already reaches the threshold without a cut to any of those prices.
Evidence
The best historical evidence is the record of the offer itself. NovoCare’s August 2025 enrollment form documents the free initiation prescription. A July 2026 patient brochure describes the same benefit, and the public terms and prescriber resources still advertised it in November 2026. That is roughly 15 months of documented history, with a standing enrollment process and no stated sunset. Novo’s rare-bleeding-disorder trial program appears in April 2020 materials and in current terms. That shows Novo can run a trial offer for years. One program in a different market is not a measured renewal rate.
The offer is specific. Adults with an on-label diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) who are new to Wegovy and meet the published criteria can receive one full 28-day supply of the 0.25 mg injection. The FDA label specifies that dose once a week for the first four weeks for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Under the NovoCare terms, uninsured patients can qualify, government-program enrollees are excluded, and no insurer or other third party can be billed for the free fill. NovoCare describes home shipment, and the published materials disclose no mandatory dispensing or shipping charge or required follow-on purchase.
The terms let Novo amend or withdraw the offer. But it does not have the calendar deadline that applies to the separate paid $199 injection promotion. Novo’s November 4 filing also reports a US submission for a Wegovy pill indication in MASH. That shows continued investment in the indication. It does not promise that the injection offer will stay open.
The history of paid offers makes a fallback plausible but gives little support for assuming one. Novo’s standard injection price was $499 in March 2025. It offered a $199 first fill from May 22 through June 30, followed by a $299 first fill in July that returned to $499 on subsequent fills. In November 2025, Novo lowered the standard price to $349 and offered selected starter fills at $199. Oral Wegovy then launched in January 2026 at $149 for the 1.5 mg dose. That price still appeared in the November 2026 guide. The pattern shows that Novo will discount a first fill more deeply than ongoing treatment. None of those paid offers reached $99.
The starter pill needs another $50 off before fees. Lilly’s competing Foundayo starter offer also starts at $149. Novo reported about 3.6 million US Wegovy pill prescriptions in the third quarter of 2026 and about 80% of US oral obesity new-to-brand prescriptions at its October 2 reporting endpoint (SEC filing). Those are measures across channels, not a clean read on cash demand. Management attributed much of the sequential prescription growth to Medicare Bridge volume. Still, neither the rival price nor the reported scale shows a clear need for a permanent cut to $99. A limited starter promotion through an authorized channel is the stronger fallback.
Several lower-looking prices do not clear the rules. The announced $675 list price effective January 1, 2027 is not a patient cash price. The $50 Medicare Bridge copay uses government assistance. An Ohio clinic advertised oral Wegovy from $49, but conflicting membership fees leave the required total unclear, and Novo’s authorization of the final price was not established. These distinctions matter because the test is the cost of a full fill under an authorized offer, not the lowest number in an ad.
What's non-obvious
Wegovy does not need to get cheaper for this question to resolve Yes. The ordinary cash price guide answers what most people pay. The separate MASH terms answer whether a defined group can get one full month from the manufacturer at or below the threshold. The free initiation prescription is not a sample or enrollment in a clinical study. It is a full labeled starter fill under public terms, with no insurer billing or required purchase. Neither the fact that it is free nor the fact that it is for a liver indication excludes it under the stated criteria.
The distinction changes what to watch. A new retail price guide could leave the forecast’s main reasoning untouched. A revised MASH enrollment form that removes uninsured patients, adds a required charge, or sets an early sunset would matter more than a modest cut to the pill price.
Uncertainties
There is no public commitment to keep the MASH program redeemable through December 31, 2027, and no systematic renewal data for comparable offers. Novo could retire a launch-era benefit, narrow enrollment, or replace it with a different form of support. The published terms establish the offer’s design, not individual redemptions or future operating hours.
There is also a narrow risk that a free prescription is read as something other than a self-pay purchase. The stronger reading is that it qualifies because the rules ask whether a patient can obtain a full month without insurance or government assistance and expressly allow first-fill promotions. Redemption on the date matters; delivery on that date does not. The clearest evidence will be dated NovoCare terms and confirmation that qualifying prescriptions were still accepted at the stated price that day. If that route closes, the next thing to check is a manufacturer-backed starter promotion with a full month’s supply and an all-in price at or below $99.
Forecast history
| Date | Forecast |
|---|---|
| 89% chance of yes |
Sources Prolepsia read
- NovoCare price guidewww.novocare.com
- # We Are With You Every Step of the Waywww.rebinyn.com
- FDA labelwww.accessdata.fda.gov
- November 4 filingwww.sec.gov
- Ro introduces one-month $199 Wegovy® new patient offer and discounted Body membershipro.co
- $299 first fill in Julywww.prnewswire.com
- News detailswww.novonordisk-us.com
- News Detailswww.novonordisk.com
- Foundayo starter offerfoundayo.lilly.com
- $50 Medicare Bridge copaywww.cms.gov
The question
This question asks whether, on December 31, 2027, Novo Nordisk will offer at least one FDA-approved dose of Wegovy, either as an oral tablet or an injection, to eligible self-paying patients in the United States at a total medication price of US$99 or less per month. The question concerns the price actually available to patients purchasing Wegovy without using insurance reimbursement, rather than its wholesale acquisition cost or list price. As of November 17, 2026, Novo Nordisk offers several self-pay options in the United States. The company launched oral Wegovy in January 2026, initially offering the 1.5 mg starting dose for $149 per month. According to NovoCare's November 2026 pricing guide, injectable Wegovy is available for $349 per month at standard self-pay prices, with eligible new patients able to obtain certain introductory doses for $199 per month during their first two months. Higher-dose Wegovy HD injections are priced at $399 per month. Novo Nordisk has also announced plans to reduce the US list price of certain Wegovy formulations to $675 per month effective January 1, 2027, although this does not directly determine self-pay pricing. The forecast concerns whether further price reductions, promotional offers, or other Novo Nordisk-authorized pricing arrangements will make at least one Wegovy dose available for $99 or less per month on December 31, 2027. Background sources include Novo Nordisk's January 5, 2026 Wegovy pill launch announcement (https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916475), its February 24, 2026 pricing announcement (https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504), and NovoCare's November 2026 price guide (https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf).
How it resolves
The question resolves YES if, on December 31, 2027, Novo Nordisk or an authorized distribution partner offers at least one FDA-approved Wegovy dose, whether oral or injectable, to eligible US self-paying patients for a total medication cost of US$99 or less per month. A qualifying offer must be officially authorized, funded, or established by Novo Nordisk and available for enrollment or redemption on the resolution date. It may be a standard self-pay price or a publicly advertised promotional price, including an introductory offer for new patients, provided that a qualifying patient can actually obtain a full month's supply at that price on December 31, 2027. The offer need not be available to every US patient, but it must be available to a nontrivial class of eligible US patients under publicly stated, objective eligibility conditions. A month's supply means 28 days of treatment for weekly injections or 30 days for daily oral tablets, using the prescribed dosing schedule for the relevant product. For promotional offers, a first-month price of $99 or less qualifies even if subsequent months cost more. Prices must reflect the amount paid by an eligible patient without insurance reimbursement or financial assistance from an insurer or government program. Any mandatory medication-related dispensing, handling, or shipping charges must be included in the $99 threshold. Optional services and separately billed medical consultations are excluded, unless purchasing them is required to access the advertised price. Qualifying offers may be available through NovoCare, participating pharmacies, or authorized telehealth and distribution partners, but independent third-party discounts not authorized or funded by Novo Nordisk do not qualify. The question resolves NO if no qualifying offer is available on December 31, 2027, including if the lowest available qualifying price exceeds $99 per month. Resolution will primarily use Novo Nordisk's official US announcements, NovoCare pricing guides, published savings-program terms, and contemporaneous pricing information from authorized distribution partners. Archived versions of these materials may be used to establish offers and eligibility terms applicable on the resolution date. If official materials are unavailable, credible contemporaneous reporting and documented pricing information from authorized sellers may be consulted. If available evidence cannot establish whether a qualifying offer existed on the specified date, the question will be annulled rather than resolved based on speculation.
Fine print
All prices are expressed in nominal US dollars, without adjustment for inflation. The resolution date is December 31, 2027, using US Eastern Time. An offer must be effective and available for redemption on that date; a price reduction announced before December 31, 2027, but scheduled to begin in 2028 does not qualify. Conversely, a promotion expiring at the end of December 31, 2027, qualifies if it remains redeemable that day. Any approved Wegovy dose strength qualifies, including starter doses, maintenance doses, and newly approved formulations marketed under the Wegovy brand. Wegovy HD also qualifies as part of the Wegovy product family. Ozempic, Rybelsus, unbranded semaglutide, compounded semaglutide, and other GLP-1 medications do not qualify, even if manufactured or distributed by Novo Nordisk. Coupons or discounts that require commercial insurance coverage or reimbursement do not qualify, but Novo Nordisk-sponsored savings programs explicitly available to self-paying patients may qualify. A price available only through a mandatory subscription or membership qualifies only if all required recurring fees, allocated to one month, keep the total cost at or below $99. Promotions limited to particular states or specific eligibility groups may qualify if they are publicly offered to a meaningful group of US self-paying patients rather than privately negotiated or individually discretionary. The question evaluates actual access to the advertised monthly medication price, not whether a patient can obtain a prescription or whether Wegovy is medically appropriate for that patient. Temporary inventory shortages do not disqualify an otherwise valid offer unless the medication is generally unavailable for purchase through the advertised channel on the resolution date.
More public forecasts
Will a major US stock exchange offer trading 23 hours a day by 31 December 2027?
>99%chance of yes
Prolepsia forecast
Will front-month COMEX gold futures settle at or above US$4,400 per ounce on any trading day before 1 January 2027?
4%chance of yes
Prolepsia forecast
Will NOAA's Climate Prediction Center report a three-month Niño 3.4 index value (ONI or relative ONI, whichever CPC uses as its official index) for any season from SON 2026 to MAM 2027 higher than the peak of the 2015-16 El Niño on the same index?
84%chance of yes
Prolepsia forecast
Will Red Sea container transits through the Suez Canal return to at least 75% of their 2023 level in any month of 2027?
94%chance of yes
Prolepsia forecast
Will US payroll growth average below 100,000 jobs a month in 2027?
72%chance of yes
Prolepsia forecast
Will the US CPI index for motor vehicle insurance rise more than 5% over the 12 months to December 2027?
17%chance of yes
Prolepsia forecast